Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.

The study found that Sh-Polypeptide 9, a biomimetic peptide, enhances endothelial tubulogenesis and VEGF production more effectively than minoxidil, particularly at low concentrations, suggesting potential for hair follicle vascularization.

This study found that a novel hydrogel scaffold, cGEL, significantly increased melanin production and melanotic gene expression in human melanocytes compared to other graft materials, suggesting its potential as a superior carrier for skin grafting.

This study found that transgenic mice expressing cgVEGF164 had increased hair follicle diameter and density, potentially linked to higher phosphorylation levels of ERK1/2, AKT1, and LEF1 proteins.

This study reported that adding the topical product CG210 to oral finasteride 1mg significantly increased hair diameter more than finasteride alone in male androgenetic alopecia patients already stabilized on finasteride treatment.

This study found that sleep deprivation in mice can trigger prostatitis by activating the cGAS-STING pathway due to reduced levels of dihydrotestosterone and melatonin, resulting in a pro-inflammatory environment, while recovery sleep can mitigate these effects.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This study found that CGF may be effective in reducing inflammation and improving skin conditions in psoriasis, particularly in patients resistant to other treatments.

In this study, seven patients with refractory alopecia areata treated with concentrated growth factor and microneedling-assisted betamethasone experienced significant hair regrowth, with one achieving over 50% regrowth and six showing complete recovery, without adverse effects.

This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stem cell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.

The study on androgenetic alopecia reported that microneedling with concentrated growth factor significantly improved hair regrowth in patients over two years, without age influencing the outcome, and recorded no significant adverse reactions.

This study established a murine chronic graft-versus-host disease model with scleroderma features, showing typical skin changes and cellular infiltrates associated with the condition.

This study found that concentrated growth factor injections significantly improved hair density, hair follicle density, and hair diameter in 60 patients with androgenic alopecia, with a 93% patient satisfaction rate and no reported complications over a 6-month follow-up period.

This study found that transient activation of c-Myc in transgenic mice stimulates keratinocyte proliferation and sebocyte differentiation, affecting normal epidermal and hair follicle development.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

The scalp serum reduced scalp discomfort and symptoms without affecting skin moisture loss.

This study observed significant clinical effects, such as hair loss and testicular changes, in common quail treated with the steroids IVF-C Inj and Diane-35, especially highlighting cyproterone acetate's impact on vital organs like the liver.

This study found that the VEGF +405G/C polymorphism may be an inheritable risk factor for polycystic ovary syndrome in south Indian women.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

This article discusses a proprietary botanical lotion with potential to reverse chemotherapy-induced alopecia, restore hair cycles, and improve patient wellbeing; however, it reports no new clinical results.

This study found that the interaction between heat shock protein 90 and lamin A/C is crucial for the growth, migration, and self-aggregation of dermal papilla cells, suggesting a potential role in alopecia areata mechanisms.

In this study, researchers found that a specific genetic variant in the INSR gene is linked to severe insulin resistance and hyperandrogenemia in type A insulin resistance syndrome, suggesting the benefit of exon sequencing for accurate diagnosis and treatment.

This study observed that NSG-hu-BLT mice developed graft-versus-host disease characterized by CD8+ T lymphocyte-related cell death in the skin and liver, which may affect their utility in other research areas.

This study reports that metreleptin treatment in a boy with congenital generalized lipodystrophy significantly improved metabolic complications and overall health outcomes during the first year of therapy.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.